GLP-1 Eligibility Requirements: BMI Thresholds, Comorbidities, and When Physicians Can Override Them

Eligibility for GLP-1 medications is frequently misunderstood on both ends of the spectrum. Some patients who qualify are told by non-specialist providers that they do not meet criteria. Others who fall outside the labeled thresholds are surprised to learn that clinical judgment allows for exceptions in defined situations. A precise understanding of how eligibility criteria work—and where the boundaries flex—helps patients enter clinical conversations with accurate expectations.

The FDA-Labeled Thresholds

The approved indication for GLP-1 medications in chronic weight management specifies two eligibility pathways based on body mass index:

• BMI ≥ 30 kg/m² (obesity): eligible without requiring a comorbid condition
• BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity: eligible with the appropriate comorbidity documentation

These are the thresholds that appear in FDA prescribing information for semaglutide 2.4 mg (Wegovy) and tirzepatide (Zepbound). They are also the criteria most insurers use as the primary filter for prior authorization decisions.

What counts as a weight-related comorbidity

For patients with BMI between 27 and 29.9, a qualifying comorbidity is required. The prescribing information identifies specific conditions; major recognized categories include:

• Type 2 diabetes or prediabetes (impaired fasting glucose or impaired glucose tolerance)
• Hypertension (documented diagnosis, not just elevated readings without a diagnosis)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides meeting clinical thresholds)
• Obstructive sleep apnea (particularly relevant since tirzepatide received a specific FDA indication for OSA in 2024)
• Established cardiovascular disease (myocardial infarction, stroke, peripheral arterial disease)
• Nonalcoholic steatohepatitis (NASH) / metabolic-associated fatty liver disease
• Polycystic ovary syndrome (PCOS) in appropriate clinical contexts

The BMI Limitation: Clinical Context Matters

BMI is a population-level screening tool with well-documented limitations at the individual level. It does not account for lean body mass, adipose tissue distribution, or ethnicity-specific metabolic risk. Clinical and epidemiological research has established that metabolic risk—including type 2 diabetes risk, cardiovascular disease risk, and fatty liver disease risk—occurs at lower BMI thresholds in South Asian, East Asian, and some other non-White populations compared to White European populations.

The World Health Organization and several major diabetes and cardiovascular societies have proposed ethnicity-adjusted BMI thresholds, recommending that South Asian patients, for example, be considered for metabolic intervention at BMI thresholds of 23–25 rather than 27–30. The FDA-labeled thresholds do not yet reflect these recommendations, but clinicians practicing at academic medical centers and obesity medicine specialty practices may apply clinical judgment in evaluating metabolic risk beyond the labeled BMI criteria.

Physician override: when clinical judgment allows prescribing below labeled thresholds

Physicians in the United States may prescribe any approved medication off-label when their clinical judgment supports a therapeutic benefit. For GLP-1 medications, off-label use below the BMI thresholds is most defensible when:

• The patient has a metabolic profile that substantially exceeds their BMI-based risk (e.g., HbA1c of 6.2%, hypertension, and hypertriglyceridemia in a patient with BMI 25)
• Prior weight management interventions have consistently failed despite documented adherence
• The clinical benefit of weight reduction is clearly established for the patient’s primary condition

Such decisions must be documented in the medical record with explicit clinical rationale, and the patient must be counseled that the prescribing is off-label with respect to FDA indications. Insurance coverage will not apply under these circumstances.

Age and Special Population Considerations

Adolescents

Wegovy received FDA approval for chronic weight management in adolescents aged 12 and older with BMI at or above the 95th percentile for age and sex in 2022. Zepbound does not currently have an adolescent indication. This is an area of active regulatory and clinical development, and criteria for adolescent GLP-1 use are evolving.

Older adults

The STEP trials enrolled adults up to age 75. Older patients often present with sarcopenic obesity (reduced lean mass with excess adiposity) in which the absolute BMI may understate the degree of metabolic impairment. Physicians prescribing GLP-1 medications in older adults typically combine them with resistance exercise and protein monitoring specifically because of the lean mass preservation concern.

Patients with eating disorders

Active anorexia nervosa or bulimia nervosa are generally considered clinical contraindications to GLP-1 prescribing for weight management, given the appetite suppression mechanism and the risk of exacerbating restriction behaviors or triggering binge-purge cycles in susceptible individuals. History of an eating disorder without current active symptoms requires careful individual assessment.

Maintaining Eligibility Over Time

An aspect of GLP-1 eligibility that is less commonly discussed is the requirement for ongoing treatment to maintain the achieved weight loss. When GLP-1 medications are discontinued, weight regain occurs in most patients within one to two years. This is not a treatment failure—it reflects the underlying biology of a chronic condition—but it does mean that eligibility criteria as a one-time threshold does not adequately capture the long-term prescribing decision.

Physicians managing patients on long-term GLP-1 therapy should document ongoing clinical benefit periodically, as some insurance plans require proof of sustained response (typically defined as at least 5% weight loss from treatment initiation) at intervals of 6 to 12 months to continue coverage authorization.